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Abstract
Background: Many men with elevated prostate-specific antigen (PSA) levels in serum do not have aggressive prostate cancer 
and undergo unnecessary biopsy. Retrospective studies using cryopreserved serum suggest that four kallikrein markers can 
predict biopsy outcome.
Methods: Free, intact and total PSA, and kallikrein-related peptidase 2 were measured in cryopreserved blood from 6129 men 
with elevated PSA (≥3.0 ng/mL) participating in the prospective, randomized trial Prostate Testing for Cancer and Treatment. 
Marker levels from 4765 men providing anticoagulated plasma were incorporated into statistical models to predict any-grade 
and high-grade (Gleason score ≥7) prostate cancer at 10-core biopsy. The models were corrected for optimism by 10-fold cross 
validation and independently validated using markers measured in serum from 1364 men. All statistical tests were two-sided.
Results: The four kallikreins enhanced prostate cancer detection compared with PSA and age alone. Area under the curve 
(AUC) for the four kallikreins was 0.719 (95% confidence interval [CI] = 0.704 to 0.734) vs 0.634 (95% CI = 0.617 to 0.651, P < 
.001) for PSA and age alone for any-grade cancer, and 0.820 (95% CI = 0.802 to 0.838) vs 0.738 (95% CI = 0.716 to 0.761) for 
high-grade cancer. Using a 6% risk of high-grade cancer as an illustrative cutoff, for 1000 biopsied men with PSA levels 
of 3.0 ng/mL or higher, the model would reduce the need for biopsy in 428 men, detect 119 high-grade cancers, and delay 
diagnosis of 14 of 133 high-grade cancers. Models exhibited excellent discrimination on independent validation among men 
with only serum samples available for analysis.
Conclusions: A statistical model based on kallikrein markers was validated in a large prospective study and reduces 
unnecessary biopsies while delaying diagnosis of high-grade cancers in few men.
Risk of death from prostate cancer is strongly associated with 
levels of prostate-specific antigen (PSA) in blood measured in 
middle-aged men (1). Evidence from randomized screening 
trials in Europe shows that PSA-based screening can reduce 
deaths from prostate cancer (2–4), but also leads to overdiag-
nosis and the risk of overtreatment among elderly men with 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License  
(http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in  
any medium, provided the original work is properly cited.
 at Tam
pere U
niversity Library. D
epartm
ent of H
ealth Sciences on N
ovem
ber 17, 2016
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
Bryant et al. | 2 of 6
a
r
t
ic
le
a
r
t
ic
le
a limited life expectancy (5,6). Although the PSA test detects 
an increased risk of prostate cancer at an early stage of the 
disease, it has low specificity (7) such that most men with an 
elevated PSA either do not have prostate cancer or have low-
risk disease that is unlikely to affect quality or length of life 
if left untreated. An elevated PSA is the main indication for 
the approximately one million prostate biopsies performed 
per annum in the United States (8). Annual prostate cancer 
incidence in the United States is close to 250 000, illustrating 
the unmet need for markers that contribute specificity beyond 
that of total PSA in order to discriminate between men with 
cancers likely to influence the length or quality of life and 
those with indolent disease or benign conditions associated 
with PSA elevation in blood.
Previous research suggested that a panel of free PSA 
(fPSA), “intact” PSA (iPSA—detecting only noncatalytic single-
chain free PSA but not multichain-free PSA internally cleaved 
between Lys145 or Lys146 [9]), and total PSA (tPSA), as well as 
human kallikrein–related peptidase 2 (hK2) measured in blood, 
is more accurate in predicting the outcome of prostate biopsy 
than total PSA alone among previously unscreened (10–12) 
and previously screened (11,12) men and men with a previous 
negative biopsy (13). Decision analyses showed that a statisti-
cal model based on the four kallikrein markers in blood can 
improve clinical decision-making about biopsy for men with 
a PSA above 3 ng/mL (10,11,14). These data suggest that the 
number of men undergoing biopsy could be reduced to half 
using 20% or greater cancer risk as a tentative threshold for 
biopsy, with approximately 20% of cancers remaining unde-
tected among previously unscreened men. However, most of 
these cancers would be low-grade and low-stage cancers typi-
cally associated with overdiagnosis, while few high-grade can-
cers would be missed.
The Prostate Testing for Cancer and Treatment (ProtecT) 
study in the United Kingdom is a prospective randomized con-
trolled trial evaluating the cost-effectiveness of conventional 
treatment modalities in PSA-detected clinically localized pros-
tate cancer. A total of 8565 of 82 428 (10.4%) men recruited to 
ProtecT had a PSA of 3.0 ng/mL or greater and were offered 
a standard 10-core prostate biopsy. Of the 7413 participants 
receiving biopsies, 2894 were found to have evidence of pros-
tate cancer (15,16). In previous studies, serum samples had 
been used to measure the four kallikrein markers. However, it 
is well recognized that ethylenediaminetetraacetic acid (EDTA) 
anticoagulated plasma has advantages over serum with free 
and intact PSA, being less prone to degradation in plasma, ena-
bling more accurate biomarker analyses with samples shipped 
to laboratories distant from the point of care (9,17). The major-
ity of participants enrolled in ProtecT had EDTA anticoagu-
lated blood collected, which provided unique opportunities 
to compare the kallikrein markers measured in plasma vs 
serum. Previous evaluations of the four kallikrein markers 
were limited to men undergoing sextant prostate biopsies 
(10–13), while the study reported herein has the added value 
of assessing the markers in the more contemporary extended 
10-core biopsy protocol used in ProtecT (15), as this leads to 
higher rates of cancer detection (18,19). We performed retro-
spective measurements of four kallikrein markers (tPSA, fPSA, 
iPSA, and hK2) in cryopreserved EDTA anticoagulated blood or 
serum in the context of a large randomized prospective clini-
cal trial involving contemporary extended 10-core biopsies to 
determine whether this panel of markers improves prediction 
of biopsy outcomes compared with total PSA and age.
Methods
Patient Cohort
In the ProtecT study, 228 926 men aged 50 to 69 years were invited 
between 2001 and 2008 to receive PSA testing. Of those, 82 429 
(36%) participants were tested, 8565 men with a serum PSA 
measurement of 3.0 ng/mL or greater were invited to undergo a 
10-core prostate biopsy, 7471 (87%) men were biopsied, and pros-
tate cancer was detected in 2637 participants. Two men with 
missing age information at biopsy and three men with missing 
Gleason grading were omitted from all analyses. Cryopreserved 
blood was retrieved for 82% of biopsied ProtecT participants: 
EDTA anticoagulated plasma from 4765 men, serum from 1860 
men, and both plasma and serum from 496 men. Participants 
had consented to sample collection and analysis by enroll-
ment in the Prostate Cancer Mechanisms of Progression and 
Treatment (ProMPT) study (ethics approval NRES 01/04/061).
Pathological Analysis
Assessment of biopsies was undertaken blind to marker results 
by urological pathologists using standardized protocols and 
agreed-upon reporting proformas (20), cancers were graded 
using the standard Gleason system (21), as detailed in a recent 
publication providing information on the processing and report-
ing of prostate cores and changes in Gleason scores over time 
(22).
Laboratory Methods
For consented individuals undergoing PSA testing within the 
ProtecT study, blood was collected, centrifuged, and frozen at 
-80° C. Anticoagulated plasma or serum was obtained after cen-
trifugation at 3000 g for 10 minutes within 30 to 60 minutes of 
venipuncture. Immunoassays for fPSA, tPSA (17,23), iPSA, and 
hK2 (24,25) were performed as previously reported (11) using 
cryopreserved samples shipped on dry ice for analysis in Hans 
Lilja’s laboratory at the Wallenberg Research Laboratories, 
Department of Laboratory Medicine, Lund University, Skåne 
University Hospital, Malmö, Sweden. Sample aliquots were sub-
ject to two freeze-thaw cycles, and analyses were performed 
with researchers blinded to prostate biopsy outcome.
Statistical Methods
Previous statistical models were based on kallikrein levels meas-
ured in serum for previously unscreened men undergoing sex-
tant prostate biopsy as part of the European Randomized Study 
of Screening for Prostate Cancer (ERSPC) study in Rotterdam 
(10,11). As levels of some of the kallikrein markers differ in 
anticoagulated plasma vs serum and the biopsied men in the 
ProtecT cohort were subjected to extended 10-core biopsy, we 
generated new prediction models. We used multivariable logis-
tic regression to build models predicting presence of any-grade 
or high-grade disease on biopsy based on a man’s age, tPSA, 
fPSA, iPSA, and hK2. Restricted cubic splines with knots at the 
tertiles were included in the model for tPSA and fPSA but not 
iPSA and hK2. Predictions for men with a PSA level of greater 
than 25 ng/mL were based on tPSA levels alone. The use of 
splines for tPSA and fPSA, but not iPSA or hK2, and the use of 
a 25 ng/mL PSA cutoff were predetermined based on our prior 
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research, and the only model fitting was to estimate an intercept 
and coefficients for each marker and nonlinear term. We report 
the area under the curve (AUC), or discrimination, of the newly 
developed models. AUCs were compared with models based on 
standard clinically available predictors using the DeLong test 
(26). We also investigated whether the model based on the four-
kallikrein panel could reduce the number of men undergoing 
biopsy without delaying the diagnosis of high-grade disease in 
many men. We used decision curve analysis (27) to investigate 
the potential clinical effects of our models. All reported statis-
tics based on modelling were corrected for overfit using 10-fold 
cross-validation. As serum samples were available for some 
men in the cohort, we conducted exploratory analyses applying 
our previously developed models to this subgroup. All P values 
reported are two-sided. Analyses were conducted using Stata 
12.0 (StataCorp., College Station, TX).
Results
Characteristics of the 6129 biopsied men with blood samples are 
shown in Table 1. Anticoagulated plasma (primary analysis) was 
available from 4765 men (3032 with no cancer, 1733 with can-
cer), and serum (secondary analysis) was available from another 
1860 men (1221 with no cancer and 639 with cancer). Finally, 
we measured the four kallikrein markers in aliquots from 496 
men who had both plasma and serum samples (Supplementary 
Table  1, available online). Overall, prior PSA testing was low 
among biopsied men (18% for men providing plasma and 16% 
for men providing serum).
The discriminatory accuracy of each combination of kal-
likrein markers, as measured in EDTA anticoagulated plasma, 
is outlined in Table 2. The discriminatory accuracy for the base 
model (age plus tPSA), as measured by the AUC, was 0.634 (95% 
confidence interval [CI] = 0.617 to 0.651) for any-grade prostate 
cancer. Adding fPSA, iPSA, and hK2 to this model improved the 
predictive accuracy (AUC 0.719 [95% CI = 0.704 to 0.734], incre-
ment 0.085, P < .001). Use of the base model to predict evidence 
of Gleason score 7 or higher (high-grade) prostate cancer at 
10-core biopsy gave an AUC of 0.738 (95% CI = 0.716 to 0.761), 
while the additional kallikrein markers statistically significantly 
enhanced the AUC to 0.820 (95% CI = 0.802 to 0.838; increment 
0.082, P < .001) (Table 2).
To explore the implications of using the models in clinical 
practice, we conducted a decision analysis to simulate out-
comes if biopsy decisions had been based on various cutpoints 
from the model. The results are shown in Table 3 and Figure 1. 
For an illustrative threshold representing a 6% risk of Gleason 
score 7 or higher (high-grade) disease, use of this model would 
reduce the number of biopsies by 428 per 1000 biopsied men 
(43%), detect 119 high-grade cancers, and delay the diagnosis 
of 14 of 133 high-grade cancers, four of which would have had 
primary Gleason grade 4.  A  decision-curve analysis demon-
strates that use of the model contributes added clinical value 
(Supplementary Figure 3, available online).
In a secondary analysis, we examined the properties 
of the four kallikrein markers measured in serum from 
another 1860 ProtecT participants (complete data shown in 
the Supplementary Materials, available online). Applying the 
previously reported “ERSPC-Rotterdam” (11) model improved 
the AUC compared with the base model (PSA plus age) from 
0.665 to 0.709 (increment of 0.043, P = .010) for evidence of any-
grade cancer at biopsy, and from 0.785 to 0.836 (increment of 
0.052, P  =  .010) for high-grade cancer at biopsy. However, as 
the “ERSPC-Rotterdam” model underestimated risk for both 
endpoints (Supplementary Figure  1B, available online), and 
ERSPC used sextant biopsies in contrast to the minimum of 
a 10-core prostate biopsy used in ProtecT, we reestimated the 
coefficients of the kallikrein markers among men providing a 
Table 1. Characteristics of men in the ProtecT study cohort*
EDTA anticoagulated blood plasma Serum
Characteristics
No cancer detected
n = 3032, 64%
No. (%)
Diagnosed with cancer
n = 1733, 36%
No. (%) P
No cancer detected
n = 1221, 66%
No. (%)
Diagnosed with cancer
n = 639, 34%
No. (%) P
Clinical characteristics
 Age (IQR), y 62 (58 to 66) 63 (59 to 67) <.001 62 (58 to 66) 63 (59 to 67) .005
 Prior PSA screen 629 (21) 232 (13) <.001 207 (17) 83 (13) .024
 Unknown 63 (2.1) 35 (2.0) 27 (2.2) 13 (2.0)
 Total PSA (IQR), ng/mL 4.3 (3.6 to 5.7) 5.4 (3.9 to 8.6) <.001 4.5 (3.6 to 5.8) 5.6 (4.2 to 9.7) <.001
 Free PSA (IQR), ng/mL 1.00 (0.76 to 1.37) 0.97 (0.70 to 1.46) .3 0.97 (0.71 to 1.35) 0.92 (0.68 to 1.46) .7
 Intact PSA (IQR), ng/mL 0.40 (0.27 to 0.58) 0.41 (0.26 to 0.66) .095 0.38 (0.25 to 0.57) 0.43 (0.27 to 0.70) <.001
 hK2, ng/mL 0.043 (0.030 to 0.062) 0.049 (0.035 to 0.073) <.001 0.041 (0.029 to 0.061) 0.053 (0.036 to 0.081) <.001
Tumor characteristics
 Gleason sum score
≤ 6 1099 (63) 464 (73)
7 542 (31) 143 (22)
≥ 8 92 (5.3) 32 (5.0)
 Stage
T1 1016 (59) 330 (52)
T2 331 (19) 88 (14)
T3 127 (7.3) 63 (10)
T4 4 (0.2) 2 (0.3)
Unknown 255 (15) 156 (24)
* The cohort underwent a 10-core prostate biopsy and had EDTA-anticoagulated plasma and/or serum available for retrospective measurements of total, free, and 
intact prostate-specific antigens (PSAs) and hK2, in cryopreserved sample aliquots. Data are median (interquartile range) or frequency (percentage). IQR = interquar-
tile range; hK2 = human kallikrein-related peptidase 2; PSA = prostate-specific antigen.
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serum sample in the ProtecT study and performed an inter-
nal validation of the updated model again utilizing 10-fold 
cross-validation. The AUC now improved from 0.665 to 0.757 
(increment 0.092, P < .001) for evidence of any-grade cancer, 
and from 0.785 to 0.859 (increment 0.075, P < .001) for high-
grade cancer as shown in Supplementary Table  2 (available 
online). Next, we evaluated whether the discriminatory prop-
erties of the kallikrein marker measurements were different 
in cryopreserved serum vs anticoagulated plasma using paired 
serum and plasma samples from 496 ProtecT participants 
(Supplementary Table 3, available online). We found no differ-
ences in the predictive accuracy of the markers measured in 
serum compared with plasma.
Finally, as an external validation of the model developed to 
predict high-grade cancer based on kallikrein markers meas-
ured in anticoagulated plasma from 4765 biopsied ProtecT 
participants, we assessed the discriminatory accuracy of this 
model using 1364 biopsied ProtecT participants with only serum 
samples available to measure the four kallikrein markers and 
excluding 496 ProtecT participants with both anticoagulated 
plasma and serum samples available. Using this independent 
group of 1364 biopsied ProtecT participants, our external vali-
dation showed that the model exhibits excellent discriminatory 
accuracy (AUC = 0.849, 95% CI = 0.814 to 0.883) (Supplementary 
Data Section 5, available online).
Discussion
In this study we demonstrate that a panel of four kallikrein mark-
ers—total PSA, free PSA, intact PSA, and hK2—can predict the 
result of prostate biopsy. A  statistical model based on the four 
markers improved this prediction above and beyond both PSA 
and age, as well as beyond a combination of total and free PSA 
(Table 2). A decision analysis indicated that use of the statistical 
model to guide biopsy decisions would reduce the number of men 
receiving unnecessary biopsies, without substantially affecting 
the diagnosis of Gleason score 7 or higher (high-grade) cancers.
Two initial studies on the Göteborg arm of the ERSPC demon-
strated that the panel of markers improved prediction of biopsy 
outcome for both unscreened men (10) and those with a previous 
Table 2. Discriminatory accuracy of each kallikrein model*
Model
Plasma
AUC (95% CI) Increment over “Age + total PSA” (P value)
Any-grade prostate cancer
 Age + total PSA 0.634 (0.617 to 0.651)
 Age + total PSA and free-to-total PSA ratio 0.710 (0.695 to 0.725) 0.076 (P < .001)
 Age + panel of four kallikrein markers 0.719 (0.704 to 0.734) 0.085 (P < .001)
High-grade prostate cancer
 Age + total PSA 0.738 (0.716 to 0.761)
 Age + total PSA and free-to-total PSA ratio 0.799 (0.779 to 0.819) 0.060 (P < .001)
 Age + panel of four kallikrein markers 0.820 (0.802 to 0.838) 0.082 (P < .001)
* This table outlines the three combinations of markers for predicting any-grade or Gleason score 7 or higher (high-grade) cancer at 10-core prostate biopsy based on 
kallikrein marker measurements in anticoagulated plasma provided by 4765 biopsied ProtecT participants. Areas under the curve were compared with models based 
on standard clinically available predictors using the DeLong test (26). All statistical tests were two-sided. CI = confidence interval; PSA = prostate-specific antigen.
Table 3. Results of differing biopsy strategies per 1000 men screened at varying thresholds for risk of any-grade cancer or high-grade cancer 
among men with anticoagulated plasma
Threshold
Biopsies
Any-grade prostate 
cancer
Gleason score 7 or 
higher (high-grade)
Primary Gleason 
score 4 or higher*
Performed Avoided (%) Found Delayed Found Delayed Found Delayed
Risk of any-grade cancer
 Biopsy all men 1000 0 (0) 364 0 133 0 47 0
 Risk by age and total PSA
≥20% 997 3 (0.3) 363 0 133 0 47 0
≥30% 642 358 (36) 264 99 111 22 41 6
 Risk by age and panel of four kallikrein markers
≥20% 834 166 (17) 334 30 129 4 46 1
≥30% 545 455 (46) 264 100 116 17 43 4
Risk of high-grade cancer
 Biopsy all men 1000 0 (0) 364 0 133 0 47 0
 Risk by age and total PSA
≥4% 974 26 (2.6) 357 7 132 1 47 0
≥6% 876 124 (12) 332 32 127 6 44 3
≥8% 715 285 (28) 284 79 117 16 42 5
≥10% 533 467 (47) 235 129 105 28 39 8
 Risk by age and panel of four kallikrein markers
≥4% 734 266 (27) 313 51 127 6 46 1
≥6% 572 428 (43) 270 94 119 14 43 4
≥8% 442 558 (56) 229 135 110 23 42 5
≥10% 361 639 (64) 203 161 103 30 39 8
* Includes cases with any Gleason Grade 5 component.
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PSA in the normal range (28). Our results confirm these findings. 
The assays were subsequently modified, and a new statistical 
model was built based on a group of unscreened men in the 
Rotterdam arm of ERSPC. This was termed the “Rotterdam” model 
and was shown to improve the prediction of biopsy outcome 
over and above PSA in several independent validation cohorts, 
including unscreened men (11,14), men with prior screening (29), 
those with prior negative biopsy (13), and those subject to clini-
cal work-up before biopsy (12). The AUC results in these previ-
ous studies are very similar to those found here, including an 
AUC of 0.820 for high-grade cancer, representing an increment of 
0.082 over age and PSA alone. For instance, in unscreened men in 
ERSPC, we reported an AUC of 0.825, 0.049 higher than the base 
model (11), and for previously screened men the AUC was 0.793, 
an increment of 0.094 beyond the base model (29).
The Rotterdam model was also shown to predict clinical cancer 
endpoints in men who were never screened from the Malmö Diet 
and Cancer study, a population-based cohort of 11 063 Swedish 
men aged 45 to 73 years who provided blood between 1991 and 
1996. Subsequent diagnosis of prostate cancer was assessed by 
linking with the Swedish Cancer Registry, updated to the end of 
2006, and this occurred in 943 men. Rates of PSA screening were 
very low in Sweden during the study. The Rotterdam model was 
applied to a subset of men with a total PSA level 3.0 ng/mL or 
more at baseline. The concordance index for clinical diagnosis of 
cancer was higher for the Rotterdam model compared with PSA 
alone (0.65 vs 0.75, P < .001). For every 1000 men with a total PSA 
level 3 ng/mL or more at baseline, the model would classify as 
high-risk 131 of 152 (86%) of the cancer case patients diagnosed 
clinically within five years, and 421 men would be classified as 
low-risk by the panel and recommended to forgo biopsy. Of these, 
only two men would be expected to be diagnosed with advanced 
prostate cancer (clinical T3 to T4 or metastases) within five years. 
Hence, while some men with a low score on the Rotterdam model 
including the four kallikrein markers do indeed have biopsy-
detectable cancer, only a very small proportion have aggressive 
disease that would become apparent over time.
The current study goes above and beyond the previous research 
not only in terms of size—with a sample size approaching all pre-
vious papers on the kallikrein markers combined—but also in the 
use of plasma samples, which appear to be more appropriate for 
analysis in clinical care, as the biomarkers are less prone to decay 
in plasma compared with serum samples. Moreover, patients in 
the study underwent a minimum of 10 core biopsies, rather than 
the outdated sextant biopsy used in previous studies. Our study 
also provides clear evidence that the statistical model based on 
the four kallikrein markers could be used in everyday clinical 
practice in order to aid decisions about prostate biopsy.
The study has a number of limitations that would need to be 
addressed in subsequent research. First, fresh samples would 
need to be assayed in a routine clinical laboratory rather than 
in a research setting using cryopreserved samples. Second, the 
ProtecT trial protocol offered biopsies to all men with PSA lev-
els of 3 ng/mL or greater, and notably 87% of men accepted the 
offer of a biopsy. In routine clinical practice, a man presenting to 
a urologist with an elevated PSA would be subjected to clinical 
work-up, including assessment of benign disease and frequently 
a repeat PSA (30). Biopsy might not be indicated if the PSA is lower 
on repeat testing or if the PSA elevation is attributed to a benign 
cause. It may be that some of the information provided by the 
kallikrein model is already captured in such a clinical work-up. If 
so, it is plausible that while the kallikrein model may be of value 
where all men with elevated PSA are biopsied, it is not of value for 
men selected for biopsy according to a urologist’s clinical judg-
ment. Third, the ProtecT cohort does not reflect clinical practice 
in the United Kingdom, where little opportunistic PSA testing 
takes place in the community (31) in contrast with many other 
countries where PSA testing and retesting prevails.
A definitive four-kallikrein panel evaluation will require the 
prospective analysis of samples taken from men with elevated 
PSA levels in whom urologists have made the clinical judgment 
to perform a biopsy. The cohort should include all-comers, 
irrespective of prior screening, PSA cutoff used, or biopsy his-
tory. Kallikrein markers should be measured from plasma in a 
clinical laboratory within one or two days of the blood draw. 
The biopsy would involve the 12 or 14 core approaches com-
mon in US practice. Marker values should be incorporated into 
a prespecified statistical model including data on digital rectal 
examination and history of prior biopsy. Such studies are cur-
rently underway.
In conclusion, we provide evidence that a panel of four kal-
likrein markers, incorporating total PSA, free PSA, intact PSA, 
Figure 1. Clinical implications of various biopsy strategies using a model developed to predict the risk of Gleason score 7 or higher (high-grade) prostate cancer based 
on four kallikrein markers measured in anticoagulated plasma collected from 4765 biopsied ProtecT participants. The graph illustrates the results of differing biopsy 
strategies per 1000 biopsied ProtecT-participants, with the x-axis denoting the risk of high-grade cancer and the y-axis indicating the number of men biopsied (black 
line) or detected with evidence of high-grade cancer (green line) using different biopsy strategies. The dotted vertical blue line illustrates a tentative cutpoint (6% risk 
of high-grade cancer) at which only 572 of 1000 of the men would be biopsied, which would result in the detection of 119 of 133 high-grade cancers.
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and hK2, is superior to total PSA alone in predicting the result of 
prostate biopsy. The markers differentially detected high-grade 
disease. In a decision analysis we found that implementation 
of a statistical model based on the markers would reduce by 
close to half the number of unnecessary biopsies undertaken, 
while delaying diagnosis of only a small number of high-grade 
cancers. These findings need to be confirmed in prospective 
research using clinical cohorts.
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